EntityMed

Company Overview

Snapshot

Founded in January 2021 by Lior Yadin, EntityMed is a Health Tech & Life Sciences company with 11–50 employees. The company has raised $2.55M across three funding rounds and holds one patent. In July 2023, EntityMed secured a grant, signaling ongoing development and support for its AI-driven solutions.

Business overview

EntityMed is a digital health company focused on enhancing the aesthetic industry for both clinics and patients. The company's core product is the EntityMed AI Simulator, which uses sophisticated AI algorithms to realistically visualize post-treatment appearances for injectables with high clinical accuracy. This technology serves as a lead generator for aesthetic practices, improving conversion rates and managing treatment expectations for clinicians and patients. EntityMed operates in the Health Tech & Life Sciences sector, specifically within Digital Healthcare and Patient Engagement, targeting healthcare providers, patients, and the cosmetics industry globally, with a strong presence in North America.

Strategic signal

In June 2023, EntityMed was highlighted for its innovative use of Generative AI in plastic surgery, specifically for its AI Simulator that visualizes post-treatment outcomes. This development signals the company's commitment to leveraging advanced AI to address critical pain points in the aesthetic industry, offering a technological edge that can drive patient engagement and clinical efficiency. For investors, this indicates a strong product-market fit and potential for scalability within the rapidly evolving digital health and aesthetic sectors.

Company Intelligence Q&A

What is EntityMed's primary offering?

EntityMed's primary offering is the EntityMed AI Simulator, which uses sophisticated AI algorithms to realistically visualize the post-treatment appearance of injectables, aiming to improve the aesthetic industry for clinics and patients.

When was EntityMed founded and by whom?

EntityMed was founded in January 2021 by Lior Yadin, who serves as the Founder and CEO.

What was a key financial milestone for EntityMed in 2023?

In July 2023, EntityMed secured a grant, contributing to its total capital raised of $2.55M.

Which investor participated in EntityMed's January 2022 funding round?

In January 2022, Mangrove Capital Partners participated as a lead investor in EntityMed's funding round.

How does EntityMed's technology benefit aesthetic practices?

EntityMed's AI Simulator has proven to be a significant lead generator for aesthetic practices, improving conversion rates for both existing and new patients and helping manage treatment and outcome expectations.